Loading clinical trials...
Loading clinical trials...
Pioglitazone for the Treatment of Idiopathic Gastroparesis (PIOGAS Study)
The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.
Objective • The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index Daily Diary (GCSI-DD) in patients with Idiopathic Gastroparesis Secondary objectives of this study include: * To determine the effects of pioglitazone on other symptoms associated with gastroparesis using the Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) and the Gastrointestinal Symptom Rating Scale (GSRS), * To determine the effects of pioglitazone on gastric emptying as measured by the 13C- Spirulina breath test, * To determine the effects of pioglitazone on satiety as measured by a liquid caloric test * To determine the effects of pioglitazone on depression and anxiety using the Beck Depression Inventory and State-Trait Anxiety Scores, * To determine the effects of pioglitazone on Quality of Life using the PAGI-QoL and Short Form (SF)-36 questionnaire, * To determine the effects of pioglitazone on markers of inflammation (CRP and ESR) and serum cytokine levels * To determine the nature and incidence of adverse effects from a 12-week course of pioglitazone. Treatment group • Pioglitazone (30 mg po qd) Population • Age 18 years or older at registration with nausea, vomiting, and other symptoms suggestive of patients with chronic nausea and vomiting of presumed gastric origin, with symptomatic gastroparesis. Study duration * Up to 4 weeks of screening prior to pioglitazone treatment * 8 weeks of treatment starting at initial dose of pioglitazone * 4 weeks of washout period * Length of recruitment: 16 months Sample size justification * Total of 23 patients * Primary comparison: Baseline PAGI-SYM score versus 4, 8, and 12 weeks. Number of clinical centers • Johns Hopkins Bayview Medical Center.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Start Date
October 24, 2019
Primary Completion Date
March 15, 2025
Completion Date
March 18, 2025
Last Updated
April 30, 2025
14
ACTUAL participants
Pioglitazone 30 mg
DRUG
Lead Sponsor
Johns Hopkins University
NCT03876288
NCT06803589
NCT06046833
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions